SYBX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Munich
NASDAQ GM

synlogic inc (SYBX) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNLOGIC INC (SYBX)
\

Related News

No related news articles were found.

synlogic inc (SYBX) Related Businessweek News

No Related Businessweek News Found

synlogic inc (SYBX) Details

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

74 Employees
Last Reported Date: 03/12/19

synlogic inc (SYBX) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $25.2K
Advisor
Total Annual Compensation: $817.3K
Compensation as of Fiscal Year 2017.
synlogic inc
Synlogic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

Synlogic, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 338,000 compared to USD 354,000 a year ago. Operating loss was USD 13.697 million compared to USD 11.636 million a year ago. Net loss was USD 12.946 million compared to USD 11.165 million a year ago. Basic loss per share was USD 0.51 compared to USD 0.55 a year ago.

Synlogic, Inc. to Report Q1, 2019 Results on May 09, 2019

Synlogic, Inc. announced that they will report Q1, 2019 results at 5:00 PM, Eastern Standard Time on May 09, 2019

Synlogic, Inc., Q1 2019 Earnings Call, May 09, 2019

Synlogic, Inc., Q1 2019 Earnings Call, May 09, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

SYBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SYBX.
View Industry Companies
 

Industry Analysis

SYBX

Industry Average

Valuation SYBX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 95.2x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SYNLOGIC INC, please visit www.synlogictx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.